N-Acetyl-L-Leucine
Ataxia-Telangiectasia
IntraBio IncPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Ataxia-Telangiectasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin NHS Tayside | Phase 4 | BB |
Letrozole NHS Tayside | Phase 4 | BB |
Pioglitazone NHS Tayside | Phase 4 | BB |
Daunorubicin St. Jude Children's Research Hospital | N/A | D |
ETOPOSIDE St. Jude Children's Research Hospital | N/A | D |
View all 16 →
Same molecule, other indications
N-Acetyl-L-Leucine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →